Top Markets
#1 Black Phoenix Black Phoenix +335.94%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +66.31%
#4 Gold Park Gold Park +58.04%
#5 Acurast Acurast +39.65%
#6 OpenEden OpenEden +34.31%
#7 BasedHype BasedHype +27.14%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +21.88%
#9 Cryptopia Cryptopia +21.54%
#10 Avantis Avantis +18.65%
Coin of the day
Black Phoenix Black Phoenix
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
TFF Pharmaceuticals, Inc. TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Inc.

TFFP
Peringkat dalam Saham #40710
Operating as a clinical-stage biopharmaceutical company, TFF Pharmaceuticals,... Operating as a clinical-stage biopharmaceutical company, TFF Pharmaceuticals, Inc., leverages its proprietary Thin Film Freezing (TFF) technology platform for the advancement and commercialization of therapeutic products across the United States and Australia. A primary emphasis is placed on creating inhaled dry powder formulations to address various pulmonary ailments and disorders. Its two leading drug candidates, both currently in Phase II clinical trials, include TFF Voriconazole Inhalation Powder, designed to combat invasive pulmonary aspergillosis, and TFF Tacrolimus Inhalation Powder, aimed at preventing lung transplant rejection. Beyond these, the company's pipeline features other dry powder products like a cannabidiol substance targeting various epilepsy syndromes, anxiety, insomnia, and pain; an Inhaled SARS-CoV2 Monoclonal Antibody for COVID-19 patients; Niclosamide Inhalation Powder, intended for human tapeworm infections and COVID-19; and a range of other vaccines. Strategic partnerships are also central to its operations, including a licensing arrangement with the University of Texas at Austin for inhaled dry powder drug development, a joint development pact with Augmenta Bioworks, Inc. for the inhaled SARS-CoV2 monoclonal antibody, and a broad licensing and collaboration agreement with UNION therapeutics A/S. Established in 2018, the company maintains its headquarters in Austin, Texas.
Harga Saham
$0.065
Terakhir disinkronkan: 2025-01-10
Kapitalisasi Pasar
$94.10K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan TFF Pharmaceuticals, Inc. (TFFP)

Kategori

Healthcare
Rasio P/E untuk TFF Pharmaceuticals, Inc. (TFFP)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari TFF Pharmaceuticals, Inc., rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk TFF Pharmaceuticals, Inc. dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.